B960, a new 34,000 sq ft wet laboratory building on Babraham Research Campus, is fully let ahead of completion

BioMed Realty has completed the lease-up of a 34,000 sq ft purpose-built, fully-fitted wet laboratory building on the Babraham Research Campus ahead of scheduled completion.

Due for completion in February 2024, this new building – B960 – will see BioMed Realty’s footprint at the Campus grow to more than 130,000 sq ft across three buildings.

B960 is already fully occupied. NASDAQ-listed Insmed and biotechnology start-up Xap Therapeutics have agreed to take 17,000 sq ft and 10,000 sq ft respectively. Mosaic Therapeutics, a graduate of the Babraham Research Campus’ start-up programme, Accelerate@Babraham, takes the remaining 6,800 sq ft of fully-fitted space.

“BioMed Realty’s latest lease announcements encapsulate the ethos of Babraham Research Campus – a location that continues to provide critically undersupplied research and development grow-on space for life science start-ups and scale-ups,” said Bill Kane, BioMed Realty president of East Coast and UK Markets.

“By investing in the mission-critical facilities that will help nurture innovation, our joint venture with Babraham Research Campus will help provide the UK’s life sciences industry with a path for growth and allow the sector to continue competing globally.”

Derek Jones, CEO, Babraham Research Campus, added: “Our ongoing development of the Campus is designed to continually enhance our exceptional Campus ecosystem.”